2024
Aiming the magic bullet: targeted delivery of imaging and therapeutic agents to solid tumors by pHLIP peptides
Reshetnyak Y, Andreev O, Engelman D. Aiming the magic bullet: targeted delivery of imaging and therapeutic agents to solid tumors by pHLIP peptides. Frontiers In Pharmacology 2024, 15: 1355893. PMID: 38545547, PMCID: PMC10965573, DOI: 10.3389/fphar.2024.1355893.Peer-Reviewed Original ResearchTumor microenvironmentTherapeutic agents to solid tumorsTargeted intracellular deliverySolid tumorsImmune cellsPHLIP technologyTargeted delivery of imagingPre-clinicalDelivery of imagingTherapeutic payloadsTumorTargeted deliveryIntracellular deliveryTumor imagingSimultaneous targetingClinical applicationTherapeutic deliveryCell typesSurface of cellsPHLIP peptidePHLIPDeliveryTarget biomarkersCellsMagic bulletpHLIP targeted intracellular delivery of calicheamicin
DuPont M, Klumpp C, Iraca M, Allababidi D, Visca H, Engelman D, Andreev O, Moshnikova A, Reshetnyak Y. pHLIP targeted intracellular delivery of calicheamicin. International Journal Of Pharmaceutics 2024, 654: 123954. PMID: 38428548, DOI: 10.1016/j.ijpharm.2024.123954.Peer-Reviewed Original ResearchM2 tumor-associated macrophagesTreatment of solid tumorsTumor-associated macrophagesTherapeutic agents to tumorsTumor-stroma interfaceAgents to tumorsInhibited tumor growthPolarized M2 macrophagesTreatment of tumorsAntibody-drug conjugatesTumor massLiquid tumorsSolid tumorsImmune cellsTumor growthM2 macrophagesTumorPH low insertion peptideBiodistribution studiesIntracellular deliveryIn vivoTumor coreCalicheamicinMacrophagesTreatment
2023
Tumor treatment by pHLIP-targeted antigen delivery
DuPont M, Visca H, Moshnikova A, Engelman D, Reshetnyak Y, Andreev O. Tumor treatment by pHLIP-targeted antigen delivery. Frontiers In Bioengineering And Biotechnology 2023, 10: 1082290. PMID: 36686229, PMCID: PMC9853002, DOI: 10.3389/fbioe.2022.1082290.Peer-Reviewed Original ResearchAnti-HA antibodiesAntigen deliveryHigh titersTumor cellsTriple-negative breast tumorsCancer cellsDifferent vaccination schemesNegative breast tumorsHA epitopeAntigen therapyImmunized miceImmune cellsNeo-antigensT cellsSignificant tumorsVaccination schemeViral infectionTherapeutic efficacyBreast tumorsHepatic clearanceImmune systemMelanoma tumorsTumorsPeptide epitopesAdjuvant
2022
Eradication of tumors and development of anti-cancer immunity using STINGa targeted by pHLIP
Moshnikova A, DuPont M, Visca H, Engelman D, Andreev O, Reshetnyak Y. Eradication of tumors and development of anti-cancer immunity using STINGa targeted by pHLIP. Frontiers In Oncology 2022, 12: 1023959. PMID: 36330464, PMCID: PMC9622777, DOI: 10.3389/fonc.2022.1023959.Peer-Reviewed Original ResearchTumor-associated macrophagesCancer-associated fibroblastsSTING agonistsT cellsTumor microenvironmentDendritic cellsCT26 tumorsM2-type tumor-associated macrophagesAnti-cancer immunityTumor-free miceEradication of tumorsActivation of cytokinesNovel STING agonistSuppressor cellsSingle doseImmune cellsIntratumoral hemorrhageTherapeutic effectTumor stromaImmune memoryNude miceAdditional injectionTumorsCancer cellsMice